Expert Interview
Discussing sebetralstat and Kalvista's Phase 3 KONFIDENT trial data in treating hereditary angioedema (HAE)
Ticker(s): KALVInstitution: Penn State University
- Professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine at Penn State University.
- Currently manages over 120 patients with hereditary angioedema and has written guidelines for international management of urticaria, hereditary angioedema and rhinitis with more than 300 publications.
- Clinical research and clinical care focuses include asthma, COPD, alpha-1-antitrypsin deficiency, urticaria, hereditary angioedema, immunodeficiency, vaccine response and other respiratory, allergic and immunologic diseases.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
